HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro and in vivo characterization of intrinsic sympathomimetic activity in normal and heart failure rats.

Abstract
Clinical studies conducted with carvedilol suggest that beta-adrenoceptor antagonism is an effective therapeutic approach to the treatment of heart failure. However, many beta-adrenoceptor antagonists are weak partial agonists and possess significant intrinsic sympathomimetic activity (ISA), which may be problematic in the treatment of heart failure. In the present study, the ISAs of bucindolol, xamoterol, bisoprolol, and carvedilol were evaluated and compared in normal rats [Sprague-Dawley (SD)], in rats with confirmed heart failure [spontaneously hypertensive heart failure (SHHF)], and in isolated neonatal rat cardiomyocytes. At equieffective beta1-adrenolytic doses, the administration of xamoterol and bucindolol produced a prolonged, equieffective, and dose-related increase in heart rate in both pithed SD rats (ED50 = 5 and 40 microgram/kg, respectively) and SHHF rats (ED50 = 6 and 30 microgram/kg, respectively). The maximum effect of both compounds in SHHF rats was approximately 50% of that observed in SD rats. In contrast, carvedilol and bisoprolol had no significant effect on resting heart rate in the pithed SD or SHHF rat. The maximum increase in heart rate elicited by xamoterol and bucindolol was inhibited by treatment with propranolol, carvedilol, and betaxolol (beta1-adrenoceptor antagonist) but not by ICI 118551 (beta2-adrenoceptor antagonist) in neonatal rat. When the beta-adrenoceptor-mediated cAMP response was examined in cardiomyocytes, an identical partial agonist/antagonist response profile was observed for all compounds, demonstrating a strong correlation with the in vivo results. In contrast, GTP-sensitive ligand binding and tissue adenylate cyclase activity were not sensitive methods for detecting beta-adrenoceptor partial agonist activity in the heart. In summary, xamoterol and bucindolol, but not carvedilol and bisoprolol, exhibited direct beta1-adrenoceptor-mediated ISA in normal and heart failure rats.
AuthorsR N Willette, N Aiyar, T L Yue, M P Mitchell, J Disa, B L Storer, D P Naselsky, J M Stadel, E H Ohlstein, R R Ruffolo Jr
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 289 Issue 1 Pg. 48-53 (Apr 1999) ISSN: 0022-3565 [Print] United States
PMID10086986 (Publication Type: Journal Article)
Chemical References
  • Adrenergic beta-Agonists
  • Adrenergic beta-Antagonists
  • Carbazoles
  • Ligands
  • Propanolamines
  • Carvedilol
  • Xamoterol
  • Iodocyanopindolol
  • Cyclic AMP
  • bucindolol
  • Bisoprolol
Topics
  • Adrenergic beta-Agonists (pharmacology)
  • Adrenergic beta-Antagonists (pharmacology)
  • Animals
  • Animals, Newborn
  • Bisoprolol (pharmacology)
  • Carbazoles (pharmacology)
  • Carvedilol
  • Cell Membrane (metabolism)
  • Cells, Cultured
  • Cyclic AMP (metabolism)
  • Decerebrate State
  • Dose-Response Relationship, Drug
  • Heart Failure (metabolism, physiopathology)
  • Heart Rate (drug effects)
  • Iodocyanopindolol
  • Ligands
  • Male
  • Myocardium (metabolism)
  • Propanolamines (pharmacology)
  • Radioligand Assay
  • Rats
  • Rats, Sprague-Dawley
  • Xamoterol (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: